KENILWORTH, N.J. — Merck & Co. says a new type of cholesterol drug reduced heart attacks, deaths and other complications of heart disease in a huge, late-stage study.
The positive result announced Tuesday was a surprise. Three major drugmakers — Pfizer, Eli Lilly and Roche — have each seen promising drugs of the same type fail after many years and millions of dollars spent on testing.
Merck tested the medicine, anacetrapib (an’uh-SET’-trah-pib), in a study including 30,000 people.
The Kenilworth, New Jersey-based company said it won’t release detailed results until a medical conference in August. That’s standard practice, but Merck raised questions about how well the medicine works by noting the company will consult with outside experts before deciding whether to seek regulatory approval to sell the drug.
